
Handbook of Experimental Pharmacology

Volume 248

Editor-in-Chief

J.E. Barrett, Philadelphia

Editorial Board

V. Flockerzi, Homburg

M.A. Frohman, Stony Brook

P. Geppetti, Florence

F.B. Hofmann, München

M.C. Michel, Mainz

C.P. Page, London

W. Rosenthal, Jena

K. Wang, Qingdao

More information about this series at <http://www.springer.com/series/164>

Kathleen A. Grant • David M. Lovinger
Editors

The Neuropharmacology of Alcohol

 Springer

Editors

Kathleen A. Grant
Department of Behavioral Neuroscience
Oregon Health & Science University
Portland, Oregon
USA

David M. Lovinger
Laboratory for Integrative Neuroscience
National Institutes of Health
Bethesda, Maryland
USA

ISSN 0171-2004 ISSN 1865-0325 (electronic)
Handbook of Experimental Pharmacology
ISBN 978-3-319-96522-2 ISBN 978-3-319-96523-9 (eBook)
<https://doi.org/10.1007/978-3-319-96523-9>

Library of Congress Control Number: 2018952524

This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2018

All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG.
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

Preface

This volume of the *Handbook of Experimental Pharmacology*, “The Neuropharmacology of Alcohol,” was an exciting and challenging editorial effort. Our understanding of the pharmacology of the simple organic compound ethanol (referred to as alcohol in this volume) has flourished in the past 40 years. This volume focuses on the alcohol’s central nervous system (CNS) effects and its behavioral pharmacology related to abuse potential. Many of alcohol’s initial actions on brain targets that were identified in the late 1980s and early 1990s have stood the test of time and technological developments; however, far more depth and breadth has been added to our understanding of alcohol’s pharmacology in the past two decades. With this reality in mind, it was difficult to assemble 20 of the most important topics for this volume. There are regrettable gaps in the neurotransmitter systems covered and the extent of phenotypic outcomes related to chronic alcohol exposure. Nevertheless, representative mechanisms of alcohol’s neuropharmacology are presented, we hope to the satisfaction of the interested reader. We have organized the volume by general emphasis on neurotransmitter systems, neuropeptides, and ion channels as well as newer topics including neuroimmune systems, genomic mechanisms, and a current review of preclinical animal and human clinical studies of pharmacotherapy developments.

The gamma-aminobutyric acid (GABA) and glutamatergic systems were arguably the first receptor systems found to have the sensitivity and selectivity expected for receptor-mediated alcohol outcomes. These amino acid neurotransmitters continue to be the most studied in alcohol neuropharmacology. Furthermore, as the field continues to define both pre- and postsynaptic mechanisms, neuroanatomical specificity and GABA–glutamate interactions are becoming prominent explanations of alcohol’s behavioral effects. Therefore, we highlight these recent developments with five chapters. A general overview of GABA_A-gated chloride channels as a target of alcohol is provided by Chandler, Overton, Ruedi-Bettschen, and Platt. This is complemented by a chapter by Lovinger on presynaptic release mechanisms implicated in G-protein coupled receptor actions on GABAergic synapses. Notable is the range of brain areas where alcohol’s effects appear to alter synaptic efficacy and the potential cross talk with other drugs of abuse. The importance of alcohol’s interaction with neurosteroid GABA_A networks is reviewed by Finn and Jimenez. The chapter by Cuzon Carlson emphasizes the

striatum as a brain area where alcohol alters the excitatory and inhibitory balance of GABAergic and glutamatergic transmission. The contribution from Rossi and Richardson also emphasizes anatomical specificity, in this case recent data implicating the cerebellum as a site for alcohol's abuse liability through effects on GABA_A channels. Next, the chapter by Hopf and Mangieri focuses on AMPA glutamate receptor (AMPA)-mediated effects of alcohol, where advances in selective antagonists have helped illuminate subunit-specific aspects of ethanol sensitivity. Finally, another ionotropic receptor system that is prominent in the abuse aspects of alcohol is the nicotinic acetylcholine receptors. The chapter by Klenowski and Tapper provides an excellent overview of separate and common targets of alcohol and nicotine, particularly in the mesolimbic pathways with an emphasis on the apparent synergistic effects leading to comorbid addiction.

We selected two monoaminergic systems to highlight in this volume. The dopaminergic system has long occupied a predominant place in neuropharmacological aspects of addictive drugs, including alcohol. In the review by Siciliano, Karkhanis, Holleran, Melchior, and Jones, dopaminergic mechanisms that are determined under similar experimental conditions and translate across species are emphasized as a way of disentangling a complex literature. In addition to dopamine, the monoamine norepinephrine (NE) is also implicated in alcohol reinforcement mechanisms, particularly in relation to arousal, emotional regulation, and stress processes. The review by Vazey, den Hartog, and Moorman emphasizes recent findings and provides new directions for better understanding how the NE system is maladaptively altered by alcohol.

The interaction of alcohol and voltage-dependent ion channels is represented by one review on calcium channels and two reviews on potassium channels. As with the GABA and glutamate systems, alcohol research has a relatively long history with voltage-sensitive calcium channels, particularly with neurophysiological disturbances such as tremors and seizures. The review by N'Gouemo takes this complex subject and emphasizes the role of neuronal homeostasis and its disruption by chronic alcohol exposure. The large conductance voltage- and calcium-dependent potassium channel (BK) and channel interactions with alcohol are reviewed by Dopico, Bukiya, and Bettinger, with an emphasis on adaptations underlying tolerance to alcohol. Comparatively new to the neuropharmacology of alcohol is disruptions in intrinsic neuronal excitability by alcohol-induced adaptations in small-conductance calcium-activated (SK), voltage-dependent, and G-protein-activated inwardly rectifying potassium channels. These potassium channel mechanisms related to alcohol and impaired neuronal firing are reviewed elegantly by Cannady, Rinker, Nimitvilai, Woodward, and Mulholland.

The aspect of alcohol's pharmacology that is receiving renewed attention is alcohol-induced neuroinflammation involving immune signaling molecules. For this subject, we have included three reviews. The first review by Kim, McCullough, Poulson, Sanz-Garcia, Sheehan, Stravitsky, and Nagy provides the important perspective of how alcohol interferes with the hepatic immune system. The second review by Coleman and Crews focuses on innate immune signals as modulators of neurocircuitry involved in the addiction to alcohol and possibilities for new

treatment approaches. This is followed by a review from Roberto, Patel, and Bajo on the effects of key cytokines on molecular properties and synaptic transmission, particularly in the extended amygdala and hippocampus. From this collection of reviews, it is clear that targets and pharmacotherapies that emerge from the cancer biology field can be repurposed to address widespread organ dysfunction, including neuroinflammation, associated with heavy alcohol drinking.

The final set of reviews on neuropharmacological mechanisms of alcohol includes a review by Schreiber and Gilpin on the extended amygdala and corticotropin-releasing factor as a basic allosteric mechanism propagating excessive drinking. This is followed by a review of alcohol's interaction with dynorphin and orexin neuropeptide systems by Anderson, Moorman, and Becker. These two systems are closely interrelated and underlie homeostatic mechanisms that likely become dysfunctional under chronic alcohol exposure, leading to changes in motivational states that increase further alcohol consumption. The final mechanistic review is by Savarese and Lasek on genomic factors induced by alcohol that can change signal transduction mechanism and gene expression integral to long-term adaptations in chronic alcohol drinking. The emergence of new pharmacological agents that target transcriptional factors promises new directions in alcohol pharmacotherapy.

We conclude this volume with highly informative, comprehensive, and timely reviews on the practical side of alcohol neuropharmacology: approaches and outcomes of preclinical and human clinical studies of alcohol pharmacotherapeutics. The review by Egli provides background on the role of animal models as sensitive and efficient for rapid screening, but emphasizes that better translational approaches are needed to have potential pharmacotherapies retain efficacy in the arena of human outpatient treatment. The final review, by Litten, Falk, Ryan, Fertig, and Leggio, provides a history and current emphasis on developing efficacious and safe compounds for treating alcohol use disorder.

We sincerely believe that this volume provides a valuable and instructive view on the state of the art in our understanding of the depth and breadth of past, present, and future neuropharmacological research on alcohol. It remains a wonder that this simple 2-carbon alcohol can result in such complex neuropharmacology. There is no doubt that as we learn more about receptor systems, their circuitry, co-modulation, adaptive capacities, and underlying functions, we will learn more about the complex processes that result in alcohol use disorders. We hope you find this volume helpful in defining important directions of this exciting research.

Portland, OR, USA
Bethesda, MD, USA

Kathleen A. Grant
David M. Lovinger

Contents

Part I Neurotransmitter Systems

GABA_A Receptor Subtype Mechanisms and the Abuse-Related Effects of Ethanol: Genetic and Pharmacological Evidence	3
Cassie M. Chandler, John S. Overton, Daniela Rüedi-Bettschen, and Donna M. Platt	
Presynaptic Ethanol Actions: Potential Roles in Ethanol Seeking	29
David M. Lovinger	
Dynamic Adaptation in Neurosteroid Networks in Response to Alcohol	55
Deborah A. Finn and Vanessa A. Jimenez	
GABA and Glutamate Synaptic Coadaptations to Chronic Ethanol in the Striatum	79
Verginia C. Cuzon Carlson	
The Cerebellar GABA_AR System as a Potential Target for Treating Alcohol Use Disorder	113
David J. Rossi and Ben D. Richardson	
Do Alcohol-Related AMPA-Type Glutamate Receptor Adaptations Promote Intake?	157
F. Woodward Hopf and Regina A. Mangieri	
Molecular, Neuronal, and Behavioral Effects of Ethanol and Nicotine Interactions	187
Paul M. Klenowski and Andrew R. Tapper	
Cross-Species Alterations in Synaptic Dopamine Regulation After Chronic Alcohol Exposure	213
Cody A. Siciliano, Anushree N. Karkhanis, Katherine M. Holleran, James R. Melchior, and Sara R. Jones	
Central Noradrenergic Interactions with Alcohol and Regulation of Alcohol-Related Behaviors	239
Elena M. Vazey, Carolina R. den Hartog, and David E. Moorman	

Part II Ion Channels

Voltage-Sensitive Calcium Channels in the Brain: Relevance to Alcohol Intoxication and Withdrawal	263
--	-----

Prosper N’Gouemo

Voltage-Sensitive Potassium Channels of the BK Type and Their Coding Genes Are Alcohol Targets in Neurons	281
--	-----

Alex M. Dopico, Anna N. Bukiya, and Jill C. Bettinger

Chronic Alcohol, Intrinsic Excitability, and Potassium Channels: Neuroadaptations and Drinking Behavior	311
--	-----

Reginald Cannady, Jennifer A. Rinker, Sudarat Nimitvilai, John J. Woodward, and Patrick J. Mulholland

Part III Neuroimmune System

Hepatic Immune System: Adaptations to Alcohol	347
--	-----

Adam Kim, Rebecca L. McCullough, Kyle L. Poulsen, Carlos Sanz-Garcia, Megan Sheehan, Abram B. Stavitsky, and Laura E. Nagy

Innate Immune Signaling and Alcohol Use Disorders	369
--	-----

Leon G. Coleman, Jr. and Fulton T. Crews

Ethanol and Cytokines in the Central Nervous System	397
--	-----

Marisa Roberto, Reesha R. Patel, and Michal Bajo

Part IV Neuropeptides and Genomics

Corticotropin-Releasing Factor (CRF) Neurocircuitry and Neuropharmacology in Alcohol Drinking	435
--	-----

Allyson L. Schreiber and Nicholas W. Gilpin

Contribution of Dynorphin and Orexin Neuropeptide Systems to the Motivational Effects of Alcohol	473
---	-----

Rachel I. Anderson, David E. Moorman, and Howard C. Becker

Transcriptional Regulators as Targets for Alcohol Pharmacotherapies	505
--	-----

Antonia M. Savarese and Amy W. Lasek

Part V Pharmacotherapy

Advancing Pharmacotherapy Development from Preclinical Animal Studies	537
--	-----

Mark Egli

Advances in Pharmacotherapy Development: Human Clinical Studies	579
--	-----

Raye Z. Litten, Daniel E. Falk, Megan L. Ryan, Joanne Fertig, and Lorenzo Leggio

Correction to: GABA_A Receptor Subtype Mechanisms and the Abuse-Related Effects of Ethanol: Genetic and Pharmacological Evidence 615
 Cassie M. Chandler, John S. Overton, Daniela Rüedi-Bettschen, and Donna M. Platt

Correction to: Presynaptic Ethanol Actions: Potential Roles in Ethanol Seeking 617
 David M. Lovinger

Correction to: Chronic Alcohol, Intrinsic Excitability, and Potassium Channels: Neuroadaptations and Drinking Behavior . . . 619
 Reginald Cannady, Jennifer A. Rinker, Sudarat Nimitvilai, John J. Woodward, and Patrick J. Mulholland

Correction to: Innate Immune Signaling and Alcohol Use Disorders . . . 621
 Leon G. Coleman, Jr. and Fulton T. Crews

Correction to: Transcriptional Regulators as Targets for Alcohol Pharmacotherapies 623
 Antonia M. Savarese and Amy W. Lasek

Correction to: Advancing Pharmacotherapy Development from Preclinical Animal Studies 625
 Mark Egli